New Super-Vaccine trial aims to protect kids from more pneumonia strains
NCT ID NCT06800261
Summary
This study is testing a new 24-strain pneumococcal vaccine (PCV24) in healthy children aged 2 months to 23 months. The main goal is to see if the vaccine is safe and if it triggers a good immune response against the bacteria that cause pneumonia and other infections. It will be compared to an existing 13-strain vaccine (Prevenar13®) in about 180 children.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Center for Disease Control and Prevention
NOT_YET_RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxian Center for Disease Control and Prevention
RECRUITINGShancheng, Shandong, 250014, China
Contact
Conditions
Explore the condition pages connected to this study.